LZ-167 is the internal name of our drug, which has passed efficacy tests in preclinical in vitro, in experimental animal models in vivo and in “off label” clinical trials in humans.
By comparing different drugs, we found that our drug compared to current available cancer treatments has an important effect against tumor cell proliferation, neoangiogenesis, in the production of metastases and in the balance of the tumor microenvironment.
It also has no undesirable effects and has beneficial effects as it is antidepressant, analgesic and anti-inflammatory.
Health care researchers working in life science laboratory, medical science technology research.
In our LK-183 tests, it has been shown to prevent the migration of tumor cells, which makes it impossible for them to invade and therefore the production of distant metastases.
Therefore, LK-183 can be effective as a preventive treatment against cancer and as a treatment to prevent metastasis.